Cancer is a diverse disease that can originate in different organs and tissues, with each type being associated with different risk factors. For instance, breast cancers have phenotypic and genotypic characteristics and recurrence risks. Similarly, leukemia is the cancer of the blood cells and solid tumors occur in organs such as lungs or liver. The American Cancer Society estimates that cancer is the second most common cause of death (22.8%), following heart diseases (26.6%). In 2015, the organization estimated 1,658,370 new cancer cases and 589,430 cancer-related deaths in the US. In the same year, EU estimated 1,359,100 cancer-related deaths. The disease is prevalent among people aged 60 and above and may account for an increase of 45% by 2030 worldwide. The diagnostic methods of cancer are complicated and involve multi-step processes. Some individuals may experience prolonged pauses during diagnosis, which can be caused by various factors related to individuals, physicians, and healthcare systems.

PART 01: Executive summary

Highlights

PART 02: Scope of the report

Market overview

Top-vendor offerings

PART 03: Market research methodology

Research methodology

Economic indicators

PART 04: Introduction

Key market highlights

PART 05: Cancer statistics

PART 06: Market landscape

Market overview

Market size and forecast

Five forces analysis

PART 07: Reimbursement and coverage: An overview

Current scenario: Validating diagnostic tests

Reimbursement structure in US

Reimbursement structure in EU

PART 08: Cancer diagnostic devices: Pricing scenario

PART 09: Market segmentation by product

Global companion cancer diagnostic devices market

Global molecular cancer diagnostic devices market

PART 10: Market segmentation by cancer type

Lung cancer

Breast cancer

Colorectal cancer

Prostate cancer

Cervical cancer

PART 11: Geographical segmentation

Cancer diagnostic devices market in Americas

Cancer diagnostic devices market in EMEA

Cancer diagnostic devices market in APAC

PART 12: Market drivers

Prevalence of cancer

Need for cost-cutting in drug discovery and

development

Demand for personalized medicines

Advances in technology

Focus on emerging countries

PART 13: Impact of drivers

PART 14: Market challenges

Unfavorable reimbursement scenario

High cost of developing companion diagnostics

Stringent regulatory framework

Lack of skilled personnel

PART 15: Impact of drivers and challenges

PART 16: Market trends

Adoption of various strategies

Increase in R&D

Product approvals and launches

PART 17: Vendor landscape

Competitive scenario

Keys news

M&A

PART 18: Key vendors

Abbott Diagnostics

Agilent Technologies

BD

bioMérieux

Qiagen

Roche Diagnostics

Other prominent vendors

PART 19: Appendix

List of abbreviations

PART 20: Explore Technavio